- Home
- TIGR vs GYRE Comparison
TIGR vs GYRE Comparison
Compare TIGR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIGR
- GYRE
- Stock Information
- Founded
- TIGR 2014
- GYRE 2002
- Country
- TIGR China
- GYRE United States
- Employees
- TIGR N/A
- GYRE N/A
- Industry
- TIGR Investment Bankers/Brokers/Service
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TIGR Finance
- GYRE Health Care
- Exchange
- TIGR Nasdaq
- GYRE Nasdaq
- Market Cap
- TIGR 1.1B
- GYRE 1.3B
- IPO Year
- TIGR 2019
- GYRE N/A
- Fundamental
- Price
- TIGR $5.68
- GYRE $13.12
- Analyst Decision
- TIGR Hold
- GYRE
- Analyst Count
- TIGR 2
- GYRE 0
- Target Price
- TIGR $6.54
- GYRE N/A
- AVG Volume (30 Days)
- TIGR 11.1M
- GYRE 53.3K
- Earning Date
- TIGR 11-12-2024
- GYRE 11-13-2024
- Dividend Yield
- TIGR N/A
- GYRE N/A
- EPS Growth
- TIGR N/A
- GYRE N/A
- EPS
- TIGR 0.19
- GYRE N/A
- Revenue
- TIGR $277,352,627.00
- GYRE $105,033,000.00
- Revenue This Year
- TIGR $62.80
- GYRE $25.32
- Revenue Next Year
- TIGR $15.56
- GYRE $12.95
- P/E Ratio
- TIGR $29.48
- GYRE N/A
- Revenue Growth
- TIGR 21.52
- GYRE N/A
- 52 Week Low
- TIGR $3.10
- GYRE $8.26
- 52 Week High
- TIGR $14.48
- GYRE $30.40
- Technical
- Relative Strength Index (RSI)
- TIGR 43.16
- GYRE 41.11
- Support Level
- TIGR $5.36
- GYRE $13.07
- Resistance Level
- TIGR $7.61
- GYRE $19.00
- Average True Range (ATR)
- TIGR 0.42
- GYRE 1.16
- MACD
- TIGR -0.16
- GYRE -0.21
- Stochastic Oscillator
- TIGR 14.22
- GYRE 7.39
About TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.